Meanwhile, TP53 mutations in medulloblastomas are well established and can be used as a prognostic and diagnostic marker: only recently, in 2016[34] and with an update in 2021[108], the World Health Organization (WHO) introduced four new diagnostic groups of this childhood brain tumor based solely on molecular genetic features. The gene discussed is TP53; the disease is medulloblastoma.